Exact Sciences (NASDAQ:EXAS) Upgraded by StockNews.com to Hold

Exact Sciences (NASDAQ:EXASGet Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Sunday.

Other equities analysts also recently issued reports about the company. Citigroup dropped their target price on Exact Sciences from $80.00 to $65.00 in a research report on Wednesday, April 27th. Wells Fargo & Company decreased their price objective on Exact Sciences from $95.00 to $80.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 23rd. Craig Hallum decreased their price objective on Exact Sciences from $100.00 to $81.00 in a research note on Wednesday, April 27th. SVB Leerink decreased their price objective on Exact Sciences from $140.00 to $130.00 and set an “outperform” rating for the company in a research note on Wednesday, February 23rd. Finally, The Goldman Sachs Group decreased their price objective on Exact Sciences from $100.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, April 19th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Exact Sciences currently has a consensus rating of “Buy” and a consensus target price of $108.77.

NASDAQ EXAS opened at $52.29 on Friday. Exact Sciences has a 52 week low of $46.15 and a 52 week high of $133.99. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.67. The business’s fifty day simple moving average is $63.79 and its 200-day simple moving average is $74.72. The firm has a market cap of $9.20 billion, a PE ratio of -12.10 and a beta of 1.23.

Exact Sciences (NASDAQ:EXASGet Rating) last issued its quarterly earnings data on Tuesday, April 26th. The medical research company reported ($1.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.08. The firm had revenue of $486.57 million during the quarter, compared to the consensus estimate of $461.86 million. Exact Sciences had a negative return on equity of 21.82% and a negative net margin of 40.26%. During the same period last year, the company earned ($0.18) EPS. Research analysts expect that Exact Sciences will post -4.26 EPS for the current year.

In other Exact Sciences news, CFO Jeffrey Thomas Elliott sold 1,839 shares of the company’s stock in a transaction on Tuesday, February 15th. The stock was sold at an average price of $79.55, for a total value of $146,292.45. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Sarah Condella sold 938 shares of the company’s stock in a transaction on Tuesday, February 15th. The shares were sold at an average price of $79.55, for a total value of $74,617.90. The disclosure for this sale can be found here. In the last three months, insiders sold 58,636 shares of company stock worth $4,443,252. Corporate insiders own 1.40% of the company’s stock.

Large investors have recently modified their holdings of the company. Mine & Arao Wealth Creation & Management LLC. lifted its position in shares of Exact Sciences by 1,562.5% in the third quarter. Mine & Arao Wealth Creation & Management LLC. now owns 266 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 250 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new position in Exact Sciences during the fourth quarter worth about $28,000. FSB Premier Wealth Management Inc. purchased a new position in Exact Sciences during the fourth quarter worth about $36,000. Masso Torrence Wealth Management Inc. purchased a new position in Exact Sciences during the fourth quarter worth about $37,000. Finally, CarsonAllaria Wealth Management Ltd. purchased a new position in Exact Sciences during the fourth quarter worth about $37,000. Institutional investors and hedge funds own 94.45% of the company’s stock.

Exact Sciences Company Profile (Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.

See Also

Analyst Recommendations for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.